Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)
CNY 20.53
(3.53%)
CNY 20.53
(3.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.41 Billion CNY | -39.63% |
| 2022 | 2.33 Billion CNY | -21.29% |
| 2021 | 2.96 Billion CNY | 25.56% |
| 2020 | 2.36 Billion CNY | 14.11% |
| 2019 | 2.07 Billion CNY | 25.34% |
| 2018 | 1.65 Billion CNY | 16.37% |
| 2017 | 1.42 Billion CNY | 26.98% |
| 2016 | 1.11 Billion CNY | 22.1% |
| 2015 | 915.98 Million CNY | 12.91% |
| 2014 | 811.28 Million CNY | 15.15% |
| 2013 | 704.54 Million CNY | 22.41% |
| 2012 | 575.55 Million CNY | 35.91% |
| 2011 | 423.47 Million CNY | -9.26% |
| 2010 | 466.71 Million CNY | 83.93% |
| 2009 | 253.75 Million CNY | 128.94% |
| 2008 | 110.84 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 270.55 Million CNY | -8.07% |
| 2024 Q3 | 216.24 Million CNY | -20.07% |
| 2024 Q1 | 294.31 Million CNY | 8.68% |
| 2023 Q1 | 501.92 Million CNY | -7.47% |
| 2023 Q2 | 318.45 Million CNY | -36.55% |
| 2023 FY | 1.41 Billion CNY | -39.63% |
| 2023 Q3 | 319.24 Million CNY | 0.25% |
| 2023 Q4 | 270.82 Million CNY | -15.17% |
| 2022 Q3 | 647.27 Million CNY | 13.1% |
| 2022 FY | 2.33 Billion CNY | -21.29% |
| 2022 Q4 | 542.45 Million CNY | -16.2% |
| 2022 Q2 | 572.32 Million CNY | -0.32% |
| 2022 Q1 | 574.17 Million CNY | -29.08% |
| 2021 Q1 | 710.47 Million CNY | -2.16% |
| 2021 FY | 2.96 Billion CNY | 25.56% |
| 2021 Q3 | 741.03 Million CNY | 4.83% |
| 2021 Q2 | 706.92 Million CNY | -0.5% |
| 2021 Q4 | 809.6 Million CNY | 9.25% |
| 2020 FY | 2.36 Billion CNY | 14.11% |
| 2020 Q1 | 398.33 Million CNY | -38.02% |
| 2020 Q4 | 726.17 Million CNY | 15.68% |
| 2020 Q3 | 627.76 Million CNY | 2.66% |
| 2020 Q2 | 611.5 Million CNY | 53.52% |
| 2019 Q2 | 444.24 Million CNY | -3.16% |
| 2019 FY | 2.07 Billion CNY | 25.34% |
| 2019 Q1 | 458.73 Million CNY | -8.52% |
| 2019 Q3 | 525.78 Million CNY | 18.36% |
| 2019 Q4 | 642.72 Million CNY | 22.24% |
| 2018 Q1 | 328.41 Million CNY | -39.12% |
| 2018 Q2 | 386.59 Million CNY | 17.72% |
| 2018 Q4 | 501.43 Million CNY | 14.96% |
| 2018 Q3 | 436.19 Million CNY | 12.83% |
| 2018 FY | 1.65 Billion CNY | 16.37% |
| 2017 Q3 | 366.3 Million CNY | 41.68% |
| 2017 FY | 1.42 Billion CNY | 26.98% |
| 2017 Q1 | 255.85 Million CNY | -17.0% |
| 2017 Q4 | 539.45 Million CNY | 47.27% |
| 2017 Q2 | 258.55 Million CNY | 1.05% |
| 2016 Q4 | 308.26 Million CNY | 3.93% |
| 2016 FY | 1.11 Billion CNY | 22.1% |
| 2016 Q1 | 231.06 Million CNY | -14.93% |
| 2016 Q3 | 296.61 Million CNY | 5.01% |
| 2016 Q2 | 282.47 Million CNY | 22.25% |
| 2015 Q1 | 197.97 Million CNY | -21.04% |
| 2015 Q4 | 271.63 Million CNY | 21.69% |
| 2015 Q3 | 223.21 Million CNY | 0.02% |
| 2015 Q2 | 223.17 Million CNY | 12.73% |
| 2015 FY | 915.98 Million CNY | 12.91% |
| 2014 Q4 | 250.73 Million CNY | 22.05% |
| 2014 FY | 811.28 Million CNY | 15.15% |
| 2014 Q1 | 178.45 Million CNY | 14.57% |
| 2014 Q2 | 176.64 Million CNY | -1.02% |
| 2014 Q3 | 205.44 Million CNY | 16.31% |
| 2013 Q4 | 155.76 Million CNY | -14.44% |
| 2013 FY | 704.54 Million CNY | 22.41% |
| 2013 Q1 | 160.46 Million CNY | -12.73% |
| 2013 Q2 | 206.25 Million CNY | 28.54% |
| 2013 Q3 | 182.05 Million CNY | -11.73% |
| 2012 Q3 | 148.11 Million CNY | 17.45% |
| 2012 Q2 | 126.11 Million CNY | 7.37% |
| 2012 Q1 | 117.45 Million CNY | 19.26% |
| 2012 FY | 575.55 Million CNY | 35.91% |
| 2012 Q4 | 183.87 Million CNY | 24.14% |
| 2011 Q3 | 71.78 Million CNY | -47.38% |
| 2011 Q4 | 98.48 Million CNY | 37.2% |
| 2011 FY | 423.47 Million CNY | -9.26% |
| 2011 Q2 | 136.41 Million CNY | 16.8% |
| 2011 Q1 | 116.79 Million CNY | -24.78% |
| 2010 Q3 | 136.06 Million CNY | 0.0% |
| 2010 FY | 466.71 Million CNY | 83.93% |
| 2010 Q4 | 155.26 Million CNY | 14.11% |
| 2009 FY | 253.75 Million CNY | 128.94% |
| 2008 FY | 110.84 Million CNY | 0.0% |